SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Peter J Halfmann  
*University of Wisconsin-Madison*

Shun Iida  
*National Institute of Infectious Diseases*

Kiyoko Iwatsuki-Horimoto  
*University of Tokyo*

Tadashi Maemura  
*University of Wisconsin-Madison*

Maki Kiso  
*University of Tokyo*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Please let us know how this document benefits you.

**Recommended Citation**

Halfmann, Peter J; Iida, Shun; Iwatsuki-Horimoto, Kiyoko; Maemura, Tadashi; Kiso, Maki; Scheaffer, Suzanne M; Darling, Tamarand L; Joshi, Astha; Ying, Baoling; Case, James Brett; Chong, Zhenlu; Whitener, Bradley; Chong, Zhenlu; Thackray, Larissa B; Boon, Adrianus C M; Diamond, Michael S; and et al, "SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters." *Nature.* 603, 7902. 687 - 692. (2022).  
[https://digitalcommons.wustl.edu/open_access_pubs/11661](https://digitalcommons.wustl.edu/open_access_pubs/11661)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters


The recent emergence of B.1.1.529, the Omicron variant, has raised concerns of escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in preclinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. Despite modelling data indicating that B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. 3,4), we observed less infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease and pathology with B.1.1.529 were also milder than with historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.

A list of affiliations appears at the end of the paper. *A list of authors and their affiliations appears at the end of the paper.
or insertions in the spike protein described so far, raising concerns of escape from protection by vaccines and therapeutic monoclonal antibodies. B.1.1.529 isolates have many changes in the RBD (G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y and Y505H). The N501Y substitution along with changes at sites (K417, E484, Q493, Q498 and N501) associated with mouse adaptation21–23 indicated that B.1.1.529 should infect mice. One study speculated that the progenitor of B.1.1.529 jumped from humans to mice, and then back into humans24. In support of this, B.1.1.529 RBD binds to mouse ACE2 (ref. 25). Last, hamsters have been a valuable animal model for assessing countermeasures against SARS-CoV-2 and variants. Hamsters are susceptible to SARS-CoV-2 infection and show similar pathological changes to those seen in lung tissues from COVID-19 patients26,27. Here, using data from several laboratories of the SAVE/NIAID consortium (Supplementary Table 1), we report on the infectivity of several B.1.1.529 isolates in mice and hamsters, two key rodent models of SARS-CoV-2 infection and pathogenesis.

**B.1.1.529 infection in mice**

Because of the presence of several amino acid alterations that are considered mouse adapting, we predicted that B.1.1.529 should infect immunocompetent mice and cause lung disease as seen with other recombinant strains (WA1/2020 N501Y) or variants (for example, B.1.351) containing N501Y substitutions. We first tested B.1.1.529 in 129 mice. Two of our laboratories independently inoculated 6–8-week-old

---

Fig. 1 | B.1.1.529 is less pathogenic in mice. a, Left, weight change in mock-infected mice (n = 4) or mice inoculated with B.1.1.529 + A701V (n = 5). B.1.1.529 (n = 3) or B.1.351 (n = 3). Middle: weight change in mice inoculated with B.1.1.529 or B.1.351 (n = 5) (** P = 0.0075, *** P = 0.0006, **** P = 0.0003). Right: weight change in mice inoculated with B.1.1.529 + A701V (n = 4), B.1.1.7 (n = 10) or B.1.351 (n = 18). Comparison between B.1.351 and B.1.1.529: * P = 0.0151, *** P = 0.0003 (3 dpi) and 0.0006 (4 dpi). Mean ± s.e.m. b, Viral RNA level in mice inoculated with B.1.1.529 or B.1.351 (n = 5) (** P = 0.0079). c, Infectious virus titre in mice inoculated with B.1.1.529 + A701V, B.1.1.529 or B.1.351 (n = 3). d, Infectious virus titre in mice inoculated with B.1.1.529 or B.1.351 (n = 5) (** P = 0.0079). e, Pulmonary function analysis as measured by whole-body plethysmography. Mean ± s.e.m. Comparison between B.1.617.2 and B.1.351: ** P = 0.0095 (n = 5 each). f, Left, weight change in mice inoculated with WA1/2020 D614G (10^3 FFU; n = 6), B.1.1.529 (10^5 FFU; n = 3), B.1.1.529 (10^4 PFU; n = 6) or B.1.1.29 (10^4

---

688 | Nature | Vol 603 | 24 March 2022
TCID50, median tissue culture infectious dose.

...recover and gain weight beginning at 5 dpi (refs. 22, 34) with SARS-CoV-2 sustain 10 to 15% loss of body weight 3 to 4 dpi yet different B.1.1.529 strains (Supplementary Tables 1 and 2). As 129 mice (plaque-forming units (PFU) or focus-forming units (FFU)) of three Syrian hamsters.

Fig. 2 | B.1.1.529 is less pathogenic in wild-type and hACE2-transgenic Syrian hamsters. a, Weight change in uninfected age-matched hamsters (n = 3) or in hamsters inoculated with B.1.1.529 or B.1.617.2 (n = 4). Mean ± s.e.m. b, Weight change in uninfected age-matched hamsters (n = 9) or in hamsters inoculated with B.1.1.529 (n = 10) or WA1/2020 D614G (n = 6). Mean ± s.e.m. (red, *P = 0.0293; red, **P = 0.0046 and 0.0014; black, ***P = 0.0021; black, ****P = 0.0001). c, Weight change in hamsters inoculated with 107, 108, 109 or 1010 PFU of B.1.1.529 or 107 PFU of B.1.617.2 (n = 4). Mean ± s.e.m. Comparison between B.1.617.2 and B.1.1.529 (107 PFU): *P = 0.0476, **P = 0.0041, 0.0041, 0.0047 and 0.0019, respectively. d, Weight change in hamsters inoculated with HP-095 D614G or B.1.1.529 (n = 3) or those inoculated with B.1.617.2 or B.1.1.529-infected (n = 4) hamsters at 7 dpi. Multifocal nodules (black arrows), ground-glass opacity (white arrowheads) and pneumomediastinum (white asterisk) are indicated. e, Viral RNA level in hamsters inoculated with WA1/2020 D614G or B.1.1.529 (n = 3) (****P = 0.0005) (7 dpi). f, Infectious virus titre of hACE2 hamsters inoculated with HP-095 D614G or B.1.1.529 (n = 4) (****P = 0.0001). g, Weight change in hACE2 hamsters inoculated with HP-095 D614G or B.1.1.529 (n = 4). Error bars indicate s.e.m. h, Survival of hACE2 hamsters after inoculation with HP-095 D614G or B.1.1.529 (n = 4) (**P = 0.0186). i, Micro-CT images of the lungs of mock-infected (n = 3) or B.1.617.2-infected (n = 4) and B.1.1.529-infected (n = 4) hamsters at 7 dpi. j, CT score for uninfected hamsters (n = 3) or those inoculated with B.1.617.2 or B.1.1.529 (n = 4) (**P < 0.0001). k, Weight change in hACE2 hamsters inoculated with HP-095 D614G or B.1.1.529 (n = 4). l, Survival of hACE2 hamsters after inoculation with HP-095 D614G or B.1.1.529 (n = 4) (**P = 0.0286). The results are from one (a, c, d, f, m) or two to three independent (b, e, experiments. Dotted lines represent the limit of detection. Statistical analysis (b–d, h, i, j, k, l, m) with two-tailed z test, f–m: two-tailed Mann–Whitney test). i, log-rank test) was performed on datasets with four or more data points. See Supplementary Table 1 for more information.

or 10–20-week-old 129 mice with 105, 106 or 107 infectious units (plaque-forming units (PFU) or focus-forming units (FFU)) of three different B.1.1.529 strains (Supplementary Tables 1 and 2). As 129 mice sustain 10 to 15% loss of body weight 3 to 4 days post infection (dpi) yet recover and gain weight beginning at 5 dpi (refs. 22, 34) with SARS-CoV-2 strains encoding N501Y substitutions, we assessed weight change with B.1.1.529 at 3 and 4 dpi. However, after inoculation with B.1.1.529, 129 mice failed to lose weight (Fig. 1a). Similarly, aged (10- to 14-month-old) C57BL/6 mice also did not lose weight after B.1.1.529 infection, whereas those infected with B.1.351 did (Fig. 1a).
We next compared viral burden in B.1.1.529- and B.1.351-infected 129 mice. At 3 dpi, 129 mice infected with B.1.351 sustained high levels of infection in the nasal wash, nasal turbinates and lungs (Fig. 1b). The levels of viral RNA in the nasal turbinates and lungs of B.1.1.529-infected mice were 10- to 100-fold lower than those in B.1.351-infected animals (Fig. 1b). Similar results were seen in a separate cohort of 129 mice at 4 dpi, with 1,000- to 100,000-fold less infectious virus recovered from nasal turbinates and lungs of animals infected with B.1.1.529 compared to B.1.351 (Fig. 1c).

Members of the group also tested B.1.1.529 in BALB/c mice. At 2 dpi, infectious virus levels in the nasal turbinate and lungs were significantly lower (=1,000-fold, \( P < 0.001 \)) in BALB/c mice infected with B.1.1.529 compared to B.1.351 (Fig. 1d). We used whole-body plethysmography\(^\text{35}\) to measure pulmonary function in infected mice. At 2 dpi, whereas B.1.351 caused an increase (\( P < 0.001 \)) in the lung enhanced pause (Penh), a marker of bronchoconstriction, B.1.1.529 did not (Fig. 1e). The ratio of peak expiratory flow (Rpef) also was decreased at 2 dpi in BALB/c mice infected with B.1.351 but not B.1.1.529 (\( P < 0.001 \), Fig. 1e).

Two of our groups tested B.1.1.529 infection in K18-hACE2 transgenic mice, which express hACE2 under an epithelial cytokeratin promoter\(^\text{44}\), and are more susceptible to SARS-CoV-2 infection\(^\text{45}\). At intranasal doses ranging from \(10^5\) to \(10^7\) infectious units of B.1.1.529, weight loss was not observed over the first 5 to 6 days of infection in younger or older K18-hACE2 mice (Fig. 1f). These data contrast with historical results with WA1/2020 D614G or variant (for example, B.1.351) SARS-CoV-2 strains\(^\text{46,24,34,36}\), which uniformly induce weight loss starting at 4 dpi. The groups separately observed reduced levels of infectious B.1.1.529 compared to WA1/2020 D614G or B.1.351 in the lower respiratory tracts at 3 dpi (Fig. 1g, h). Finally, we assessed inflammatory responses in the lungs of K18-hACE2 mice at 3 dpi. Mice inoculated with B.1.1.529 had lower levels of several pro-inflammatory cytokines and chemokines compared to those inoculated with B.1.351, with many values similar to those of uninfected controls (Fig. 1i and Supplementary Table 3). Thus, on the basis of several parameters (weight change, viral burden, respiratory function measurements and cytokine responses), B.1.1.529 seems attenuated in the respiratory tract of several strains of mice.

**B.1.1.529 infection in hamsters**

Four members of our group tested three different B.1.1.529 strains for their ability to infect and cause disease (Supplementary Table I). Whereas intranasal infection with historical or other variant SARS-CoV-2 strains generally resulted in \(10\) to \(15\)% reduction in body weight over the first week, we observed no weight loss in hamsters inoculated with B.1.1.529 (Fig. 2a–d), although animals did not gain body weight as rapidly as uninfected hamsters. Viral RNA analysis at 4 dpi showed lower levels of B.1.1.529 infection in the lungs (12-fold, \( P < 0.001 \)) compared to WA1/2020 D614G (Fig. 2e). A comparison of infectious viral burden in tissues at 3 dpi between B.1.617.2 and B.1.1.529 strains showed virtually no difference in nasal turbinates but substantially less infection of B.1.1.529 in the lungs of most animals (Fig. 2f). A comparison of viral RNA levels between WA1/2020 and B.1.1.529 in nasal washes at 4 dpi did not show substantial differences in titres.
We observed whole-body plethysmography to measure pulmonary function in infected Syrian hamsters. Starting at 3 dpi and continuing until 7 dpi, infection with B.1.617.2 caused an increase ($P < 0.05$) in the Penh, whereas B.1.1.529 infection did not (Fig. 2h, left). The Rpef was decreased at 5 and 7 dpi in animals infected with B.1.617.2 but not B.1.1.529 ($P < 0.001$; Fig. 2h, middle). Finally, hamsters infected with B.1.617.2, but not B.1.1.529, demonstrated a decrease in respiratory rate (frequency) compared to uninfected animals (Fig. 2h, right). On the basis of several functional parameters, lung infection and disease after B.1.1.529 infection was attenuated compared to that after infection with other variant strains.

We performed microcomputed tomography (micro-CT) to assess for lung abnormalities in hamsters at 7 dpi. Micro-CT analysis revealed lung abnormalities in all B.1.617.2-infected hamsters on 7 dpi that were consistent with commonly reported imaging features of COVID-19 pneumonia. In comparison, analysis of B.1.1.529-infected hamsters on 7 dpi revealed patchy, ill-defined ground-glass opacity consistent with minimal to mild pneumonia. Syrian hamsters infected with B.1.617.2 had a much higher CT disease score compared to those infected with B.1.1.529 (Fig. 2i, j).

Members of our group also compared lung pathology in Syrian hamsters after infection with B.1.617.2 or B.1.1.529. The lungs obtained from B.1.617.2-infected hamsters showed congestion and/or haemorrhage, which were absent in B.1.1.529-infected animals (Fig. 3a). Immune cell infiltration and inflammation were present in the peribronchial regions of the lungs at 3 dpi with B.1.617.2. At 6 dpi, extensive infiltration of neutrophils and lymphocytes in the alveolar space was accompanied by pulmonary edema and haemorrhage (Fig. 3b, inset), and regenerative changes in the bronchial epithelia became prominent (Fig. 3b). By contrast, in B.1.1.529-infected hamsters, small foci of inflammation in the alveoli and peribronchial regions were observed only at 6 dpi (Fig. 3b). A worse histopathology score of viral pneumonia at 6 dpi was measured after B.1.617.2 than B.1.1.529 infection (Fig. 3c). After B.1.617.2 infection, viral RNA was detected readily in the alveoli and bronchial epithelia at 3 and 6 dpi (Fig. 3d). After B.1.1.529 infection, fewer bronchial epithelial cells and alveoli were positive for viral RNA at either time point (Fig. 3d). Thus, B.1.1.529 replicates less efficiently in the lungs of Syrian hamsters, which results in less severe pneumonia compared to that resulting from the B.1.617.2 variant.

Although hamster ACE2 can serve as a receptor for the SARS-CoV-2 spike protein, some of the contact residues in hACE2 are not conserved, which could diminish infectivity. To develop a more susceptible hamster model, members of the consortium used transgenic hamsters expressing hACE2 under the epithelial cytokeratin-18 promoter. Whereas intranasal inoculation of 10^3 PFU of HP-095 D614G virus resulted in marked weight loss within the first week (Fig. 2k) and uniform mortality by 10 dpi (Fig. 2l), less weight loss and death ($P < 0.05$) were observed after infection with B.1.1.529. Moreover, 1,000- to 10,000-fold lower levels of infectious virus were measured in the lungs of B.1.617.2 transgenic hamsters challenged with B.1.1.529 than in those challenged with HP-095 D614G at 3 and 5 dpi (Fig. 2m).

As seen in wild-type Syrian hamsters, smaller differences in infection were observed in the nasal turbinates. Thus, B.1.1.529 infection in the lung is attenuated in both wild-type and hACE2 transgenic hamsters.

**Discussion**

Our experiments indicate that the B.1.1.529 variant is less pathogenic in laboratory mice and hamsters. Although these results are consistent with preliminary data in humans, the basis for attenuation remains unknown. One study indicates that B.1.1.529 replicates faster in the human bronchus and less in lung cells, which may explain its greater transmissibility and putative lower disease severity. We observed that B.1.1.529 resulted in a lower level of infection of hamster bronchial cells in vivo and lower viral burden in nasal washes and turbinates in mice compared with other SARS-CoV-2 strains. The attenuation in mice was unexpected given that B.1.1.529 has alterations in the RBD that are sites associated with adaptation for mice. The attenuation in hamsters seen by our group and others was also surprising, given that other SARS-CoV-2 variants replicate to high levels in this animal. Whereas the >30 changes in the B.1.1.529 spike protein could impact receptor engagement, changes in other proteins could affect replication, temperature sensitivity, cell and tissue tropism, and induction of pro-inflammatory responses in a species-specific manner. Our results showing attenuated B.1.1.529 infection in laboratory mice do not support the suggestion that B.1.1.529 has a mouse origin. However, infection studies in wild mice are needed to fully address this question.

Although B.1.1.529 is less pathogenic in mice and hamsters, these animals still will have utility in evaluating vaccine, antibody or small-molecule inhibitors. The mice and hamsters tested, to varying degrees, showed evidence of viral replication and dissemination to the lower respiratory tract, which could be mitigated by countermeasures. The most severe B.1.1.529 infection and disease was observed in hACE2-expressing mice and hamsters, which is consistent with findings for other SARS-CoV-2 strains and possibly related to the enhanced interactions between hACE2 and B.1.1.529 spike. Indeed, structural analysis of the B.1.1.529 spike protein in complex with hACE2 reveals new interactions formed by mutated residues in the RBD.

These in vivo studies were performed as part of the SAVE/NIAID consortium and reflect a network that communicates weekly to expedite progress on SARS-CoV-2 variants. This format had several advantages: animal experiments were reproduced across laboratories providing confidence in results; several B.1.1.529 isolates were tested limiting the possibility of sequence adaptations in a strain from one laboratory that could skew results; several strains of mice and hamsters at different ages were tested allowing for a comprehensive dataset; and the groups used overlapping metrics to evaluate infection and disease in the different animal models.

We note several limitations to our study. First, our experiments reflect data from a consortium that did not use uniform study design and metrics, which created variability in outcomes; despite this, data from several groups indicate that B.1.1.529 is attenuated in rodent models. Second, although attenuation of B.1.1.529 in mice and hamsters correlates with preliminary data in humans, evaluation in nonhuman primates and unvaccinated, previously uninfected humans is needed for corroboration. Third, we used the prevailing B.1.1.529 isolate that lacks an R346K substitution. Approximately 10% of B.1.1.529 sequences in GISAID as of the writing of this paper have an R346K sequence, and this substitution or others in gene products apart from spike might affect virulence. Although one of the B.1.1.529 isolates we tested contains an additional A701V change in spike near the furin cleavage site, it was still attenuated in mice. Fourth, detailed pathological and immunological analyses were not performed for all of the animal species studied. It remains possible that B.1.1.529 is attenuated clinically (for example, weight loss) because of defects in promoting pathological host responses.

In summary, our collective studies rapidly and reproducibly demonstrated attenuated infection in several strains of mice and hamsters. Experiments are ongoing to determine the basis for attenuation in mice and hamsters and to determine how this relates to B.1.1.529 infection in humans.

**Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-022-04441-6.

2. Torjesen, I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ 375, n2343 (2021).


Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA. 1Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan. 2Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. 3Department of Medicine, Washington University School of Medicine, St Louis, MO, USA. 4Department of Surgery, Schools of Veterinary Medicine, University of Wisconsin–Madison, Madison, WI, USA. 5Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 7Center for Childhood Infections and Vaccines of Children’s Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. 8Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 9The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan. 10Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA. 11Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA. 12Department of Oncological Sciences One-Health Consortium and One-Health Genomic Laboratory, Universidad Nacional de Colombia, Medellin, Colombia. 13Wisconsin State Laboratory of Hygiene, Madison, WI, USA. 14Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA. 15Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, Tennessee, USA. 16Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 17Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 18Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 19Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 20Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA. 21The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 22Department of Pathology & Immunology, Washington University School of Medicine, St Louis, MO, USA. 23Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA. 24Department of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 25The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis, MO, USA. 26These authors contributed equally: Peter J. Halfmann, Shun Iida, Kyoko Iwatsuki-Horimoto, Tadashi Maemura, Makio Kiso. 27E-mail: jboon@wustl.edu, mtdiandm@wustl.edu, yoshishiro.kawaoka@wisc.edu

Consortium Mount Sinai Pathogen Surveillance (PSP) study group


Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Methods

Cells

Vero-TMPRSS2 (refs. 38,39) and Vero-hACE2-TMPRSS2 (ref. 38) cells were cultured at 37 °C in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3 and 100 U ml⁻¹ penicillin-streptomycin. Vero-TMPRSS2 cells were supplemented with 5 µg ml⁻¹ blasticidin or 1 mg ml⁻¹ geneticin (depending on the cell line) and in some cultures with Plasmocin. Vero-hACE2-TMPRSS2 cells were supplemented with 10 µg ml⁻¹ puromycin. All cells routinely tested negative for mycoplasma using a PCR-based assay.

Viruses

The WAI2020 recombinant strains with substitutions (D614G and/or N501Y/D614G) were described previously 45. The B.1.1.529 isolates (hCoV-19/USA/WI-WSLH-221686/2021 (GISAID: EPI_ISL_7263803), hCoV-19/Japan/NC928-2N/2021 (NC928) (GISAID: EPI_ISL_7507055), hCoV-19/USA/NY-MHSHPSP-PV44476/2021 (GISAID: EPI_ISL_7908052), hCoV-19/USA/NY-MHSHPSP-PV44488/2021 (GISAID: EPI_ISL_7908059) and hCoV-19/USA/GA-EHC-2811C/2021 (GISAID: EPI_ISL_7171744)) were obtained from nasal swabs and passages on Vero-TMPRSS2 cells as described previously 38,39,51. Sequence differences between B.1.1.529 isolates are depicted in Supplementary Table 2. Other viruses used included: SARS-CoV-2/UT-HP095-IN/Human/2020 (HP-095; D614G), hCoV-19/USA/CA_CDC_5574/2020 (Alpha, B.1.1.7; BEIN54011), hCoV-19/USA/MD-HP01542/2021 (Beta, B.1.351), 20H/501Y.V2 (Beta, B.1.351), hCoV-19/USA/PHC658/202 (Delta, B.1.617.2) and hCoV-19/USA/WI-UW-5250/2021 (Delta, B.1.617.2; UW-5250) 45. All viruses were subjected to next-generation sequencing as described previously 64 to confirm the stability of substitutions and avoid introduction of adventitious alterations. All virus experiments were performed in an approved biosafety level 3 facility.

Animal experiments and approvals

Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381-01), University of Wisconsin, Madison (V006426), St Jude Children’s Research Hospital (assurance number D16-00043), Emory University, University of Iowa (assurance number A3021-01), Icahn School of Medicine at Mount Sinai (PROTO2021000007), BIOQUAL, Inc., and the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo (approval numbers PA19-72 and PA19-75). Virus inoculations were performed intranasally under light ketamine-xylazine sedation with 10⁴ PFU of hCoV-19/USA/WI-WSLH-221686/2021 (GISAID: EPI_ISL_7263803) or 10⁵ PFU of SARS-CoV-2 strains in 50 µl. Body weight was monitored daily. For virological and pathological examinations, four hamsters per group were euthanized at 3 and 6 dpi, and nasal turbinates and lungs were collected. The virus titres in the nasal turbinates and lungs were determined by plaque assays on Vero-TMPRSS2 cells. Human ACE2 transgenic hamsters were intranasally inoculated with 10⁵ PFU of hCoV-19/USA/WI-WSLH-221686/2021 in 50 µl. Body weight and survival were monitored daily, and nasal turbinate and lungs were collected at 3 and 5 dpi for virological analysis. In a third set of experiments, six-week-old male Syrian golden hamsters were randomized into groups of 4 to 6 and inoculated with SARS-CoV-2 via delivery of 100 µl of appropriately diluted virus in PBS equally split between both nostrils. Weight change and clinical observations were collected daily. In a fourth set of experiments, while under isoflurane anaesthesia, male 8–10-week-old hamsters were inoculated intranasally with 10⁵ PFU of WAI/2020 D614G or B.1.1.529 variant in 100 µl. In a second set of experiments, under isoflurane anaesthesia, wild-type Syrian hamsters were intranasally inoculated with 10⁴ PFU of SARS-CoV-2 strains in 50 µl. Body weight and survival were monitored daily, and nasal turbinate and lungs were collected at 3 and 5 dpi for virological analysis. In the nasal turbinates and lungs were determined by plaque assays on Vero-TMPRSS2 cells. Human ACE2 transgenic hamsters were intranasally inoculated with 10⁵ PFU of hCoV-19/USA/WI-WSLH-221686/2021 in 50 µl. Body weight and survival were monitored daily. Nasal washes were taken at 4 dpi for virological analysis.

Measurement of viral burden

Mouse studies. Tissues were weighed and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1,000 µl DMEM medium supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified by centrifugation at 10,000 × g, for 5 min and stored at −80 °C. RNA was extracted using the MagMax mirVana Total RNA isolation kit (Thermo Fisher Scientific) on the Kingfisher Flex extraction robot (Thermo Fisher Scientific). Viral RNA (V′gene) was reverse transcribed and amplified using the TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific), and data were analysed and normalized as described previously 32. Infectious virus titres were determined by plaque assay on Vero-hACE2-TMPRSS2 cells as previously published 24. The viral titres in the nasal turbinates and lungs were determined by plaque assay on Vero-TMPRSS2 cells as previously published 35. At the indicated day post infection, mice were euthanized with isoflurane overdose and one lobe of lung tissue was collected in an Omni Bead Ruptor tube filled with Tri Reagent (Zymo, number R2050-1-200). Tissue was homogenized using an Omni Bead Ruptor 24 (5.15 ms, 15 s), and then centrifuged to remove debris. RNA was extracted using a Direct-zol RNA MiniPrep Kit (Zymo, number R2051), and then converted to cDNA using a High-capacity Reverse Transcriptase CDNA Kit (Thermo, number 4368813). SARS-CoV-2 RNA-dependent RNA polymerase and subgenomic RNA were measured as described previously 28,55.
The subgenomic SARS-CoV-2 RNA levels were quantified in nasal turbinates and lungs by quantitative PCR with reverse transcription as previously published\textsuperscript{54,55}. Infectious virus titres in nasal turbinates and lungs were determined by plaque assay on Vero-TMPRSS2 cells as described previously\textsuperscript{56}.

**Hamster studies.** Lungs were collected 4 dpi and homogenized in 1.0 ml of DMEM, clarified by centrifugation (1,000 g for 5 min) and stored at −80 °C. Nasal washes were clarified by centrifugation (2,000 g for 10 min) and the supernatant was stored at −80 °C. To quantify viral load in lung tissue homogenates and nasal washes, RNA was extracted from 100 µl samples using E.Z.N.A. Total RNA Kit (Omega) and eluted with 50 µl of water. Four microlitres of RNA was used for real-time quantitative PCR with reverse transcription to detect and quantify the N gene of SARS-CoV-2 using TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific) as described previously\textsuperscript{60}. The virus titres in the nasal turbinates and lungs were determined by plaque assay on Vero E6 cells expressing human TMRPSS2 as previously published\textsuperscript{61}. RNA was extracted from clarified nasal washes using the Qiagen RNeasy extraction kit (Qiagen) following the manufacturer’s instructions. Samples were purified on the included columns and eluted in 50 µl of nuclease-free water. PCR was conducted using 4× TaqMan Fast Virus Master Mix (Thermo Fisher) and an N-gene primer/probe set.

**Plaque assay**

Vero-TMPRSS2 or Vero-TMPRSS2-hACE2 cells were seeded at a density of 1 × 10⁴ cells per well in 24-well tissue culture plates. The following day, medium was removed and replaced with 200 µl of material to be titrated serially in DMEM supplemented with 2% FBS. One hour later, 1 ml of methylcellulose overlay was added. Plates were incubated for 72 h, and then fixed with 4% paraformaldehyde (final concentration) in PBS for 20 min. Plates were stained with 0.05% (w/v) crystal violet in 20% methanol and washed twice with distilled, deionized water.

**Measurement of cytokines and chemokines**

Superior and middle lobes of the lungs from K18-hACE2 mice (mock-infected or 3 dpi) were collected, homogenized and then stored at −80 °C. After thawing, lung homogenates were centrifuged at 10,000 g for 5 min at 4 °C. Samples were inactivated with ultraviolet light in a clear, U-bottom 96-well plate (Falcon). A mouse 26-plex, bead-based Luminex assay (catalogue number EPXR260-26088-901) was used to profile cytokine and chemokine levels in clarified lung supernatants. The assay was performed according to the manufacturer’s instructions, and all incubation steps occurred on an orbital shaker set at 300 r.p.m. Briefly, 50 µl of clarified lung homogenate supernatant was combined with beads in a lidded, black 96-well plate supplied as part of the kit and incubated for 30 min at room temperature, and then overnight at 4 °C. The next day, the plate was allowed to equilibrate to room temperature for 30 min, washed 3 times with 150 µl per well of 1× wash buffer diluted, and then 25 µl per well of 1× detection antibody mixture was added for 30 min at room temperature. The plate was washed 3 times, and then 50 µl per well of 1× Streptavidin–PE solution was added for 30 min at room temperature. After washing 3 times, 120 µl per well of reading buffer was added, and the plate was incubated for 5 min at room temperature. Data were acquired on a Luminex 100/200 analyser (Millipore) with xPONENT software (version 4.3) and analysed using GraphPad Prism (version 8.0) and R (version 4.0.5).

**Micro-CT imaging**

Hamsters were inoculated intranasally with 10⁷ PFU (in 30 µl) of B.1.1.529 (strain NC928), B.1.617.2 (UW-5250) or PBS. Lungs of the infected animals were imaged by using an in vivo micro-CT scanner (Cosmoscan FX; Rigaku Corporation). Under ketamine–xylazine anaesthesia, the animals were placed in the image chamber and scanned for 2 min at 90 kV, 88 µA, field of view 45 mm and pixel size 90.0 µm. After scanning, the lung images were reconstructed by using the CosmoScan Database software of the micro-CT (Rigaku Corporation) and analysed by using the manufacturer-supplied software. A CT severity score, adapted from a human scoring system, was used to grade the severity of the lung abnormalities\textsuperscript{59}. Each lung lobe was analysed for degree of involvement and scored from 0 to 4 depending on the severity: 0 (none), 1 (minimal, 1–25%), 2 (mild, 26–50%), 3 (moderate, 51%–75%) or 4 (severe, 76%–100%). Scores for the five lung lobes were summed to obtain a total severity score of 0–20, reflecting the severity of abnormalities across the three infected groups. Images were anonymized and randomized; the scorer was blinded to the group allocation.

**Pathology**

Excised animal tissues were fixed in 4% paraformaldehyde in PBS, and processed for paraffin embedding. The paraffin blocks were cut into 3-µm-thick sections and mounted on silane-coated glass slides. Sections were processed for in situ hybridization using an RNA scope 2.5 HD Red Detection kit (Advanced Cell Diagnostics) with an antisense probe targeting the nucleocapsid gene of SARS-CoV-2 (Advanced Cell Diagnostics). Lung tissue sections were scored for pathology on the basis of the percentage of alveolar inflammation in a given area of a pulmonary section collected from each animal in each group using the following scoring system: 0, no pathological change; 1, affected area (<10%); 2, affected area (<50%, >10%); 3, affected area (≥50%); an additional point was added when pulmonary edema and/or alveolar haemorrhage was observed.

**Reagent availability**

All reagents described in this paper are available through material transfer agreements.

**Statistical analysis**

The number of independent experiments and technical replicates used are indicated in the relevant figure legends. Statistical analysis included unpaired t-tests, Mann–Whitney tests and ANOVA with multiple correction post tests.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

**Data availability**

All data supporting the findings of this study are available in the paper. There are no restrictions in obtaining access to primary data. Source data are provided with this paper.

**Code availability**

No code was used in the course of the data acquisition or analysis.


Acknowledgements This study was supported by grants and contracts from the NIH (R01 AI187155 (M.S.D.), U01 AI151810 (M.S.D. and A.C.M.B.), 75N93021C00014 (Center for Research on Influenza Pathogenesis and Transmission, Y.K. and A.G.-S.), HHSN272201400008C (Y.K.), HHSN272201700004I (Z.W.), 5N030020FOO0001A38 (Z.W.), P50OD011132 (M.S.S.), R56AI147623 (M.S.S.), HHSN272201400004C (M.S.S.), 75N93021C00017 (M.S.S.), P01 AI060699 (S.P.), RO1 AI129689 (S.P.), R01DK130425 (M.S.S.), 5T32AI007647-22 (L.A.C.), 75N93019C00051 (M.S.D.) and 75N93021C00016 (St Jude Center of Excellence on Influenza Research and Response, R.J.W. and A.C.M.B.), as well as grants from the Defense Advanced Research Projects Agency (HR0011-19-2-319 0020 (A.G.-S.)), and the Research Program on Emerging and Re-emerging Infectious Diseases (JP20ko108412, JP21ko108615, JP20ko108472 and JP21ko108104), a Project Promoting Support for Drug Discovery (JP20nko101632) and the Japan Program for Infectious Diseases Research and Infrastructure (JP21wm0125002) from the Japan Agency for Medical Research and Development (AMED). The Woodruff Health Sciences Center and Emory School of Medicine, Woodruff Health Sciences Center 2020 COVID-19 Cure Award, and the Intramural programme of the NIAID, NIH (D.C.D., R.A.S. and N.J.S.) also supported this study. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii. The piggyBac vector, pmhyGEMIE-3, was a gift from S. Moisyadi at the University of Hawaii.


Competing interests M.S.D. is a consultant for Inbio, Vir Biotechnology, Senda Biosciences, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immune. The Diamond laboratory has received funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. The Boon laboratory has received unrelated funding support in sponsored research agreements from Al Therapeutics, Abb’-Ve Inc., GreenLight Biosciences Inc., and Nano targeting & Therapy Biopharma Inc. M.S.S. serves on Advisory boards for Moderna and Ocugen. Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shinomori & Co. Ltd, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seyeaku, Shinsha Corporation and Fuji Rebio. The A.G.-S. laboratory has received unrelated research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma and Merck. A.G.-S. has paid or equity-based consulting agreements for the following companies: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperoxav, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary and Pfizer, outside the reported work. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York, outside the reported work. Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays that list Viviana Simon as co-inventor. S.P. has received unrelated research support from bioAge Laboratories and Autonomous Therapeutics Inc. The remaining authors declare no competing interests.

Additional information Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41586-022-04441-6.
Correspondence and requests for materials should be addressed to Adrianus C. M. Boon, Michael S. Diamond or Yoshihiro Kawaoaka.
Peer review information Nature thanks Emmie de Wit and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Reprints and permissions information is available at http://www.nature.com/reprints.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- a The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- □ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- □ The statistical test(s) used AND whether they are one- or two-sided
  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- □ A description of all covariates tested
- □ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- □ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- □ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  Give P values as exact values whenever possible.
- □ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- □ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- □ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection: No software was used in this study to collect data

Data analysis: Prism 8.0 was used to perform all statistical analysis. xPONENT (version 4.3) and R (version 4.0.5) were used to analyze the cytokine data.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data supporting the findings of this study are available within the paper and in the Source Data. There are no restrictions in obtaining access to primary data.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- ☑ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | No sample sizes were chosen a priori. All experiments with statistical analysis were repeated at least two independent times, each with multiple technical replicates. Experimental size of cohorts was determined based on prior experience performing studies in animals and with SARS-CoV-2 infection models (PMID: 34846168, 34668780, 37839617, 34140350, and 32571934). The studies were corroborated by independent and parallel experiments by several different groups in the SAVE/NIAID consortia. |
| Data exclusions | No data was excluded. |
| Replication | All experiments with multiple biological and/or technical replicates are indicated in the figure legends. |
| Randomization | For animal studies, mice were randomly assigned to treatment groups in an age and sex-matched distribution. All experiments were derived from animal work so no additional randomization was required in downstream analysis. |
| Blinding | No blinding was performed although several key studies were performed independently by different members of the SAVE consortium. Blinding was not performed because studies were independently corroborated by separate laboratories. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

<table>
<thead>
<tr>
<th>Materials &amp; experimental systems</th>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/a</td>
<td>Involved in the study</td>
</tr>
<tr>
<td>☑</td>
<td>Antibodies</td>
</tr>
<tr>
<td>☑</td>
<td>Eukaryotic cell lines</td>
</tr>
<tr>
<td>☑</td>
<td>Palaeontology and archaeology</td>
</tr>
<tr>
<td>☑</td>
<td>Animals and other organisms</td>
</tr>
<tr>
<td>☑</td>
<td>Human research participants</td>
</tr>
<tr>
<td>☑</td>
<td>Clinical data</td>
</tr>
<tr>
<td>☑</td>
<td>Dual use research of concern</td>
</tr>
<tr>
<td>☑</td>
<td>ChIP-seq</td>
</tr>
<tr>
<td>☑</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td>☑</td>
<td>MRI-based neuroimaging</td>
</tr>
</tbody>
</table>

Eukaryotic cell lines

Policy information about Cell lines

Cell line source(s) | Vero-TMPRSS2, Diamond and Kawaroka laboratories (not commercially available); Vero-hACE2-TMPRSS2, Graham laboratory, VRC/NIAID (available at BEI Resources, NR-54970)

Authentication | These were obtained from academic laboratories and grew and performed as expected. Cells expressing TMPRSS2 and hACE2 were validated using monoclonal antibodies and flow cytometry.

Mycoplasma contamination | All cell lines are routinely tested each month and were negative for mycoplasma.

Commonly misidentified lines (See ICAC register) | This study did not involve any commonly misidentified cell lines.

Animals and other organisms

Policy information about studies involving animals: ARRIVE guidelines recommended for reporting animal research

| Laboratory animals | Heterozygous female K18-hACE2 C57BL/6J mice (strain JAX:Bg-Tg(K18-ACE2)2Prmm/J), 5-6 month-old). Male and female C57BL/6J (strain 129S2/SvPasCrl or 129S51/SvImJ, 6-8, 10-20, or 31 week-old), and female C57BL/6 (strain 000664, 10-14 month-old) mice were obtained from The Jackson Laboratory and Charles River Laboratories. Female BALB/c mice (6-week-old) were purchased from |


Japan SLC Inc.

Five-to-six-week-old male Syrian Golden hamsters were obtained from Charles River Laboratories, Envigo, or Japan SLC Inc. The K18-hACE2 transgenic hamster line will be described in detail elsewhere [see REF 39; bioRxiv, doi:10.1101/2021.07.26.453840].

Mice were housed in groups of 4 to 5; Hamsters were housed alone. Photoperiod = 12 hr on:12 hr off dark/light cycle. Ambient animal room temperature is 70° F, controlled within ±2° and room humidity is 50%, controlled within ±5%.

<table>
<thead>
<tr>
<th>Wild animals</th>
<th>No wild animals were used in this study.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Field-collected samples</td>
<td>No field collected samples were used in this study.</td>
</tr>
<tr>
<td>Ethics oversight</td>
<td>Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381–01), University of Wisconsin, Madison (V006426), St. Jude Children’s Research Hospital (Assurance number D16-00043), Emory University, University of Iowa (assurance number A3021-01), Icahn School of Medicine at Mount Sinai (PROTO202100007), BIOQUAL, Inc., and the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo (approval numbers PA19–72 and PA19–75).</td>
</tr>
</tbody>
</table>

Note that full information on the approval of the study protocol must also be provided in the manuscript.